Overview
DeepScribe develops ambient clinical AI built around specialty-care documentation.
What DeepScribe does
DeepScribe provides ambient clinical AI with a strong focus on oncology and other specialty practices. It captures the patient conversation and uses relevant chart context to draft documentation that clinicians can review within their established workflow.
SmartPrep assembles a pre-visit summary from prior notes, laboratory results, imaging, medications and diagnoses. The medical scribe supports the encounter itself, while coding tools identify relevant E/M, ICD-10 and HCC information. Customization Studio lets the generated note follow the clinician’s specialty and preferences.
DeepScribe Embedded integrates with oncology systems including OncoEMR and iKnowMed. Its product approach follows the care journey from pre-charting through the reviewed note and coding, rather than providing a standalone transcript that must be manually reconstructed into a clinical record.
Company details
- Funding
- More than $60 million reported funding (October 2026)
Founders & leadership
Investors & backers
DeepScribe’s October 2026 recruiting material reports more than $60 million raised, naming Index Ventures and angels Alexandr Wang and Dylan Field.
- Index Ventures
- Foothill Ventures
- Bee Partners
- Industry Ventures
- Alexandr Wang
- Dylan Field
